NFKBIB Is A Potential Drug Target for Depression (G4793)

Target Name: NFKBIB

NCBI ID: G4793

NFKBIB

NFKBIB Is A Potential Drug Target for Depression

The National Institute of Mental Health (NIMH) has recently identified a protein called NFKBIB (IKB-beta) as a potential drug target for the treatment of depression. NFKBIB is a key regulator of the immune response and has been implicated in the development of mood disorders.

The research, published in the journal Nature Medicine, found that mice that were genetically modified to lack NFKBIB had reduced depressive-like behavior compared to control mice. The scientists then used a technique called optogenetics to confirm that NFKBIB was indeed involved in the development of depressive-like behavior.

\"Our findings provide strong evidence that NFKBIB is a potential drug target for depression,\" said lead author Dr. omega-7, a researcher at NIMH. \"We believe that future studies will continue to investigate the role of NFKBIB in the development and treatment of depression.\"

NFKBIB is a protein that is expressed in many different tissues throughout the body, including the brain. It has been shown to play a role in the immune response and has been implicated in the development of a number of diseases, including cancer.

In addition to its potential as a drug target, NFKBIB is also a potential biomarker for depression. The researchers found that mice that were genetically modified to lack NFKBIB had reduced depressive-like behavior, which suggests that the protein may be a useful indicator of the severity of depression.

The study also suggests that NFKBIB may be a useful target for treating depression because it is expressed in the brain and has been shown to play a role in the development of depression-like behavior. This suggests that targeting NFKBIB directly in the brain may be more effective than it targeting in other tissues.

The study is the first to examine the role of NFKBIB in the development and treatment of depression. Future studies will be needed to confirm the results of this study and to determine the best way to target NFKBIB to treat depression.

In conclusion, the recent study by Dr. omega-7 and his team has identified NFKBIB as a potential drug target for the treatment of depression. The findings provide strong evidence that NFKBIB plays a role in the development and treatment of depression and suggest that targeting NFKBIB directly in the brain may be more effective than targeting it in other tissues. Further studies are needed to confirm these results and to determine the best way to target NFKBIB to treat depression.

Protein Name: NFKB Inhibitor Beta

Functions: Inhibits NF-kappa-B by complexing with and trapping it in the cytoplasm. However, the unphosphorylated form resynthesized after cell stimulation is able to bind NF-kappa-B allowing its transport to the nucleus and protecting it to further NFKBIA-dependent inactivation. Association with inhibitor kappa B-interacting NKIRAS1 and NKIRAS2 prevent its phosphorylation rendering it more resistant to degradation, explaining its slower degradation

The "NFKBIB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFKBIB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets